Literature DB >> 16407419

Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study.

O Graesslin1, A Cortez, R Fauvet, M Lorenzato, P Birembaut, E Daraï.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) and their inhibitors are key-players in extracellular matrix and basement membrane degradation, and are involved in both physiological and malignant processes. The aim of this study was to examine MMP-2, -7 and -9 and TIMP-1 and -2 expression in normal, hyperplastic and malignant endometrium, and their relation to clinical and histological prognostic factors.
MATERIALS AND METHODS: We performed qualitative and semi-quantitative immunohistochemical analysis of 20 samples of normal endometrium (10 in the proliferative phase, 10 in the secretory phase), 39 samples of hyperplastic endometrium (17 without atypia and 22 with atypia) and 38 samples of endometrioid carcinoma, by using specific monoclonal antibodies.
RESULTS: In normal endometrium, epithelial expression of MMP-2 (P = 0.0007), MMP-7 (P = 0.0002) and TIMP-2 (P = 0.0004) was increased during the proliferative phase of the menstrual cycle. MMP-2 expression correlated negatively with TIMP-2 expression (P = 0.001, rho = 0.702). Endometrial stromal cells in the secretory phase showed strong MMP-2 expression (P = 0.004) and weak MMP-7 (P = 0.001) and TIMP-1 expression (P = 0.01). In hyperplastic endometrium, the presence of atypia was associated with lower TIMP-2 expression (P = 0.005) and was also associated with a trend towards higher MMP-2 expression. Endometrial stromal cell expression of MMP-2, -7 and -9 and TIMP-1 and -2 did not differ between hyperplastic endometrium with and without atypia. A gradient of MMP-2 and -9 expression was observed from hyperplastic endometrium to endometrial carcinomas. In endometrial carcinomas, MMP-2 expression increased (P = 0.0004) and TIMP-2 expression decreased (P = 0.0005) with the histological grade. TIMP-2 expression correlated with myometrial invasion (P = 0.005), lymphovascular space involvement (P = 0.008) and lymph node involvement (P = 0.007).
CONCLUSION: These results support the involvement of MMPs and TIMPs in endometrial carcinogenesis. Strong MMP-2 and weak TIMP-2 expression were the most potent markers of endometrial malignancies with a high risk of local and distant spread.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407419     DOI: 10.1093/annonc/mdj129

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  17 in total

1.  Comparative study of the immunohistochemical expression of tissue inhibitors of metalloproteinases 1 and 2 between clearly invasive carcinomas and "in situ" trophoblast invasion.

Authors:  Blerta Dimo; Ioannis Ioannidis; Andreas Karameris; George Vilaras; Panagiota Tzoumakari; Aphrodite Nonni; Eystratios Patsouris; Andreas C Lazaris
Journal:  Med Oncol       Date:  2011-07-24       Impact factor: 3.064

2.  A Targeted Proteomics Approach for Screening Serum Biomarkers Observed in the Early Stage of Type I Endometrial Cancer.

Authors:  Blendi Ura; Valeria Capaci; Michelangelo Aloisio; Giovanni Di Lorenzo; Federico Romano; Giuseppe Ricci; Lorenzo Monasta
Journal:  Biomedicines       Date:  2022-08-02

3.  Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells.

Authors:  Vijay Pandey; Jo K Perry; Kumarasamypet M Mohankumar; Xiang-Jun Kong; Shu-Min Liu; Zheng-Sheng Wu; Murray D Mitchell; Tao Zhu; Peter E Lobie
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

4.  MicroRNA-200b is overexpressed in endometrial adenocarcinomas and enhances MMP2 activity by downregulating TIMP2 in human endometrial cancer cell line HEC-1A cells.

Authors:  Yinmei Dai; Wei Xia; Tao Song; Xueting Su; Jie Li; Shaohua Li; Ying Chen; Wei Wang; Hongmei Ding; Xuemei Liu; Hui Li; Qiang Zhao; Ningsheng Shao
Journal:  Nucleic Acid Ther       Date:  2012-12-03       Impact factor: 5.486

5.  Endometrial miR-200c is altered during transformation into cancerous states and targets the expression of ZEBs, VEGFA, FLT1, IKKβ, KLF9, and FBLN5.

Authors:  Harekrushna Panda; Leslie Pelakh; Tsai-Der Chuang; Xiaoping Luo; Orhan Bukulmez; Nasser Chegini
Journal:  Reprod Sci       Date:  2012-05-08       Impact factor: 3.060

6.  Overexpression of the matrix metalloproteinase 11 gene is a potential biomarker for type 1 endometrial cancer.

Authors:  Gabriela Sofía Gómez-Macías; María Lourdes Garza-Rodríguez; Raquel Garza-Guajardo; Daniela Monsiváis-Ovalle; Jesús Ancer-Rodríguez; Hugo Alberto Barrera-Saldaña; Oralia Barboza-Quintana
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

7.  Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.

Authors:  Jean-Luc Brun; Annie Cortez; Bénédicte Lesieur; Serge Uzan; Roman Rouzier; Emile Daraï
Journal:  Oncol Rep       Date:  2011-12-22       Impact factor: 3.906

8.  Inhibition of histone deacetylase activity in human endometrial stromal cells promotes extracellular matrix remodelling and limits embryo invasion.

Authors:  Carlos Estella; Isabel Herrer; Stuart P Atkinson; Alicia Quiñonero; Sebastián Martínez; Antonio Pellicer; Carlos Simón
Journal:  PLoS One       Date:  2012-01-26       Impact factor: 3.240

9.  Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.

Authors:  Maria Honkavuori-Toivola; Anne Talvensaari-Mattila; Ylermi Soini; Taina Turpeenniemi-Hujanen; Markku Santala
Journal:  Tumour Biol       Date:  2012-01-21

10.  Characterization of EN-1078D, a poorly differentiated human endometrial carcinoma cell line: a novel tool to study endometrial invasion in vitro.

Authors:  Marie-Claude Dery; Celine Van Themsche; Diane Provencher; Anne-Marie Mes-Masson; Eric Asselin
Journal:  Reprod Biol Endocrinol       Date:  2007-09-25       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.